stockrow
Friday 6 November 2026
Export TPST’s income statement to Excel — free account
Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
- EPS
- +83.6%
- Free cash flow
- +67.0%
Quarter to June 2026, against a year earlier
0.38
0.08
−17.39%
Follow TPST
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | — | — | — | — | — | — | — | — | — | 0 | — | 4 | 4 | 4 | 0.0% | |
| Gross margin, % | (727.11) | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | +727.1 pt | ||||||
| EBT | (82) | (85) | (27) | (45) | (19) | (28) | (36) | (29) | (42) | (26) | (40) | (11.9%) | ||||||
| EBT margin, % | (12,566.46) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +12,566.5 pt | ||||||
| Net income | (82) | (85) | (27) | (45) | (19) | (28) | (36) | (29) | (42) | (26) | (40) | (11.9%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 59.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (7,482.76) | (62,703.32) | (3,427.41) | (633.62) | (533.72) | (97.14) | (40.18) | (24.84) | (19.51) | (6.33) | (4.48) | (54.4%) | ||||||
| Cash flow | (5,612.18) | (15,646.15) | (2,993.29) | (586.37) | (528.25) | (89.05) | (34.99) | (23.08) | (15.39) | (6.46) | (1.36) | (52.9%) | ||||||
| Capex | (235.09) | (3.08) | (4.56) | (5.65) | (1.39) | (0.46) | (0.63) | (0.14) | (0.20) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (5,847.27) | (15,649.23) | (2,997.85) | (592.02) | (529.64) | (89.51) | (35.62) | (23.22) | (15.59) | (6.46) | (1.36) | (53.1%) | ||||||
| Book value | 9,838.00 | 3,383.85 | 9,255.95 | 851.65 | 497.61 | 123.90 | 20.39 | 22.58 | 8.91 | 1.61 | (0.07) | (62.0%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 9 | +93.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/S | 83.76 | — | — | — | — | — | — | — | — | — | 17.86 | — | ||||||
| P/B | 0.51 | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/Sales | (91.41) | — | — | — | — | — | — | — | — | — | 22.37 | — | ||||||
| EV/FCF | 0.93 | — | — | — | — | — | — | — | — | — | (0.34) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (62) | (20) | (24) | (41) | (19) | (26) | (31) | (27) | (33) | (27) | (21) | (8.8%) | |||||
| Capex | (3) | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | — | 0 | (20.0%) | ||||||
| Free cash flow | (64) | (20) | (24) | (42) | (19) | (26) | (32) | (28) | (33) | (27) | (21) | (9.3%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 103 | 16 | 74 | 59 | 17 | 49 | 26 | 31 | 17 | 5 | (3) | (28.6%) | |||||
| Net debt | (114) | (17) | (77) | (63) | (17) | (37) | (21) | (33) | (30) | (8) | (1) | (25.9%) | ||||||
| Shareholders’ equity | 108 | 4 | 73 | 60 | 18 | 36 | 18 | 27 | 19 | 7 | (1) | (26.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (63.00) | (118.83) | (52.35) | (56.04) | (39.27) | (58.90) | (59.85) | (60.38) | (89.90) | (89.91) | (237.25) | (26.9) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (1,469.09) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (69.99) | 833.08 | 98.16 | (67.02) | 430.58 | 173.23 | (131.70) | (131.42) | (182.35) | (203.63) | (931.14) | (133.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 118 | 36 | 34 | 38 | 13 | 17 | 19 | 17 | 25 | 4 | — | (31.3%) | |||||
| Revenue/emp, $m | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2016 · latest quarter Sep 2017 · fundamentals updated 26 Oct 2026
Tempest Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ICU SeaStar Medical Holding Corporation | $10.2M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | Compare |
| MBRX Moleculin Biotech, Inc. | $9.2M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CURX Curanex Pharmaceuticals Inc | $9.1M | — (loss-making) | — | — | n/m | −272.32% (below 0%: shrinking) | — | 0.00% | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.1M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CALC CalciMedica Inc. | $8.9M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BLRX BioLineRx Ltd. | $8.8M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| INAB IN8bio, Inc. | $8.2M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TPST Tempest Therapeutics, Inc. | $7.5M | — (loss-making) | — | −71.57% (below 0%: shrinking) | n/m | +67.04% (above 0%: growing) | 0.00% | 0.00% | |
| Median of peers | $9.1M | — | — | — | — | −3.42% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 17 July 2026
Ownership
Directors and executive officers, together
36.20%
Matthew Angel
34.20%
Entities affiliated with Lotus Capital BVI Limited
23.20%
Sabby Volatility Warrant Master Fund, Ltd.
7.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement